Ram C V, Featherston W E
St. Paul Medical Center, Dallas.
Chest. 1988 Jun;93(6):1251-3. doi: 10.1378/chest.93.6.1251.
The availability of calcium antagonists has provided yet another therapeutic option in the management of hypertension. Calcium antagonists lower the blood pressure in hypertensive individuals while preserving the blood flow at the microcirculatory level. While all the available calcium antagonists are effective in the treatment of hypertension, they differ in their hemodynamic and pharmacologic actions. Nifedipine appears to be suitable for immediate treatment of severe hypertension and for chronic treatment of uncomplicated or refractory hypertension. In some but not all patients, co-administration of a beta-blocker is necessary to blunt reflex tachycardia. This problem is less likely with the tablet/long-acting formulation of nifedipine. Verapamil and diltiazem are useful as initial therapy for chronic mild-to-moderate hypertension. They are as effective as other first-line drugs in the treatment of uncomplicated hypertension. The heart rate with verapamil or diltiazem does not change or is slightly reduced, thus contrasting with nifedipine. Experience to date suggests that calcium antagonists do not cause adverse biochemical effects and in this respect are superior to diuretics and certain beta-blockers. Currently, verapamil is available as a sustained release preparation. In the near future, nifedipine or diltiazem may also be available in the long acting formulation to permit simplicity and to enhance patient compliance in the treatment of hypertension.
钙拮抗剂的出现为高血压的治疗提供了另一种治疗选择。钙拮抗剂可降低高血压患者的血压,同时维持微循环水平的血流。虽然所有现有的钙拮抗剂在治疗高血压方面都有效,但它们在血流动力学和药理作用方面存在差异。硝苯地平似乎适用于重度高血压的即刻治疗以及单纯性或难治性高血压的长期治疗。在一些但并非所有患者中,需要联合使用β受体阻滞剂来抑制反射性心动过速。硝苯地平的片剂/长效制剂出现这种问题的可能性较小。维拉帕米和地尔硫䓬可用作慢性轻度至中度高血压的初始治疗。它们在治疗单纯性高血压方面与其他一线药物一样有效。使用维拉帕米或地尔硫䓬时心率不变或略有降低,这与硝苯地平形成对比。迄今为止的经验表明,钙拮抗剂不会引起不良生化效应,在这方面优于利尿剂和某些β受体阻滞剂。目前,维拉帕米有缓释制剂。在不久的将来,硝苯地平或地尔硫䓬也可能有长效制剂,以便在高血压治疗中简化用药并提高患者的依从性。